Researchers have developed a new combination of compounds called AB569 which has demonstrated success at fighting deadly pathgoens like Pseudomonas aeruginosa.
List view / Grid view
Disrupting the communication between bacteria and quinolone signalling can inhibit the the production of toxins and virulence factors...
Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 million private placement. Exisiting Polyphor investors contributed to 98% of the financing.